An early-stage medical device firm, Obsidio had been structured around redefining therapeutic embolization: uncontrolled bleeding due to vascular injury or from an aneurysm rupture - typically associated to high mortality rate. Currently, in most clinical settings the treatment is transcatheter embolization - the intentional endovascular occlusion of an artery or vein. Organized around a universal gel embolic material, the Obsidio assembled team is addressing significant limitations of current available embolization devices. Pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patientÂ’s coagulopathy, the young firm's developing technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections between arteries and veins, and treat aneurysms. In August 2022 it was announced that Obsidio Inc had been acquired by Boston Scientific for an undisclosed amount
